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Abstract
Background: Benign prostatic hyperplasia (BPH) is the most prevalent disease of the prostate in elderly men. Since
Nigella sativa has been reported to show various pharmacological effects, this study was conducted to examine the effect
of N. sativa seed oil on experimental BPH.
Methods: The oil was extracted using the cold-pressing method. Fifty rats were divided into five groups of 10 each as
follows: Group 1 orally (p.o.) received normal saline; groups 2e5 were castrated and subcutaneously received 5 mg/kg
testosterone propionate for four weeks. Group 2, namely, BPH model, underwent no further treatment, Groups 3 and 4
were treated with 400 mg/kg and 800 mg/kg N. sativa seed oil, Group 5 received finasteride (0.5 mg/kg, p.o.) for 28 days.
All groups received repeated testosterone injections for the following four weeks after BPH induction. After the
treatments, rats were sacrificed and the prostate tissues removed. Wet weight, prostatic volume (PV) and prostatic index
(PI) were determined. Serum prostate-specific antigen (PSA), dihydrotestosterone (DHT), malondialdehyde (MDA) and
antioxidant levels were determined.
Results: Our results showed that oral treatment with 400 and 800 mg/kg N. sativa oil led to a significant decrease in PI,
PV, DHT concentration, PSA, and serum MDA level, and also significantly increased serum antioxidant capacity.
Conclusions: The study demonstrated that the oil seed exerted anti-BPH effects which may be associated with its
antioxidant properties in vivo.
Keywords: antioxidant level, benign prostatic hyperplasia, dihydrotestosterone, malondialdehyde, Nigella sativa seed oil,
prostate-specific antigen
1. Background
B enign prostatic hyperplasia (BPH) is themost prevalent age-related disease of the
prostate gland for men [1,2]. Its symptoms
include urinary tract obstruction, frequent uri-
nation, urinary retention, decreased diameter of
the urinary tube and pressure of urine flow, and
dribbling at the end of urination [3,4]. The dis-
ease is characterized by prostate gland enlarge-
ment due to hyperproliferation of cellular
components such as mesenchymal cells. The
most common drug treatments for BPH include
the use of a-adrenergic antagonists, 5-a-reduc-
tase inhibitors and alternative therapies such as
natural products [5].
Recent studies have shown the relationship be-
tween oxidative stress (OS) and BPH. As a measure
of OS, the level of the lipid peroxidation indicator,
malondialdehyde (MDA) increases in BPH patients
while plasma antioxidants’ are suppressed [6,7].
This implies that antioxidant therapies might have
potential application in the management of BPH.
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Alpha-adrenergic receptor blockers and 5-alpha
reductase inhibitors cause side effects, and the high
prices of some of these drugs have led to an
increasing tendency to use natural compounds as a
source of lead compounds for drug design for the
treatment of BPH or as a supplementary drug.
Studies showed that alternative and complementary
treatment is remarkable options for the manage-
ment of mild BPH patients including Serona repen,
Pygeum africanum, and Secale cereal. There are
several reasons for significant attitude for this global
approach including their availability, low cost as
well as showing better safety profile than the cur-
rent pharmaceutical medications. Furthermore, due
to the universal approach to returning to nature and
the use of natural compounds in the treatment of
incurable diseases, attention to plants along with
other natural resources has increased, among these,
it could mention to Nigella sativa that it is highly
recommended by the researches [5].
Belonging to the plant family of Ranunculaceae,
Nigella sativa is native to southwestern Asia, south-
ern Europe, northern Africa and Iran [8,9]. Mainly
cultivated for its black seeds, N. sativa has extensive
applications as a spice and medicinal plant. The
seeds are also rich sources of fixed oil, which is
renowned for a high level of unsaturated fatty acids
such as oleic, linoleic and linolenic acid. Previous
studies have further reported that these fatty acids
can prevent the proliferation of prostate cells
induced by testosterone and DHT. Additionally,
they are capable of inhibiting the 5-a-reductase, an
enzyme drug target of DHT which is known to
metabolise testosterone to dihydrotestosterone
[10e12]. N. sativa has further been demonstrated to
exert antioxidant and anti-inflammatory properties
[13,14]. No evidence has yet been reported, howev-
er, on the use of this plant to treat BPH. This study
was thus conducted to evaluate the effect of N. sativa
seed oil on rat model of BPH.
2. Materials and methods
2.1. Preparation of N. sativa seeds and oil
extraction
Cultivated N. sativa seeds were purchased from
Shahrekord Agricultural Faculty, Shahrekord, Iran.
Samples were cultivated in the region of (32 210 0000
North, 50 490 0000 East) where the average rainfall
from cultivation to harvest is reportedly 5e7 mm. A
voucher specimen (SKUMS-801) was approved by a
botanical expert (Shirmardi, Hamzeh Ali, PhD. at
the Iranian Research Center of Agriculture and
Natural Resources, P.O. Box 415, Shahrekord) and
deposited in the Herbarium of Medical Plants
Research Center affiliated to Shahrekord University
of Medical Sciences. The seeds were kept in poly-
ethene bags at 4 C and then the dried seeds were
extracted using screw less cold presses machine.
The seeds were pressed at 50 C with nozzle size
7 mm and speed of screw at 20 rpm. The crude oil
gained was kept in an amber bottle to store in the
freezer (18 C) until the next analysis [15].
2.2. Husbandry
Fifty male Wistar rats weighing between 200 and
250 g were obtained from the Pasteur Institute of
Iran (Tehran, Iran). The animals were housed under
21e23 C temperature and 12-h light and 12-h
darkness cycles for seven days to acclimatize to the
animal house. All stages of experimentation were
carried out under the regulations of the ethic com-
mittee of shahrekord university of medical sciences
(ethics code: IR.SKUMS.REC.1394.28).
2.3. Experimental design
2.3.1. Castration and testosterone-induced rat model of
BPH
First, the rats were anaesthetized using 50 mg/kg
phenobarbital and their testes were removed under
sterile conditions. After castration, penicillin
(7.14  104 IU/kg body weight) was administrated
intramuscularly according to a previously described
method [2]. Seven days later, the animals subcuta-
neously received 5 mg/kg testosterone propionate
daily for four weeks. Simultaneously, group 1, as
negative controls, were administered with normal
saline alone, group 2 were considered BPH model,
groups 3 and 4 were orally treated with 400 and
800 mg/kg of the oil of N. sativa seed, respectively,
group 5 were administered with 0.5 mg/kg oral fi-
nasteride and considered positive control [16]. The
doses of N. sativa seed oil were selected according to
previous studies [17,18]. All groups received
repeated testosterone injections for the following
four weeks after BPH induction (Fig. 1). After 28
days, the rats fasted for 24 h and blood samples
were drawn from the abdominal aorta under deep
anaesthesia. The prostate glands were then
removed for further examinations. At the end of the
experiments, rats were euthanized using a high
dose of co-administered ketamine and xylazine.
2.3.2. Determination of prostate index (PI) and volume
(PV)
After anaesthesia, the whole prostates were
collected and immediately weighed. The prostate
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weight/total body weight ratio was considered to
indicate PI [19] and the immersion of prostate in
graded acetone was measured to indicate PV [20].
2.3.3. Measurement of prostate-specific antigen (PSA)
The PSA was measured by Biotin double antibody
sandwich method utilizing an ELISA kit (Shang-
haicristal Day Biotech Co., China) according to the
manufacturer's instructions.
2.3.4. Determination of dihydrotestosterone (DHT)
DHT was measured by mean of standard ELISA
kits (Shanghaicristal Day Biotech Co., China) ac-
cording to the manufacturer's instructions (Shang-
haicristal Day Biotech Co., China). 10 ml of standard
control and serum sample was poured into the plate
and 50 ml biotin and 50 ml conjugate were added to
them and incubated for 1 h at room temperature
and then the plate was washed with a washing
machine (Chrom, Asrs Atlantis Washer) and 100 ml
of the substrate with the dye solution added to it and
for the sample concentration determination was
placed inside the Elisa reader. According to the OD
standards, the diagram was drawn and the con-
centration of the samples in ng/ml was determined
according to the diagram. From control serum was
used for quality control of the kit and to ensure the
accuracy of the test result, the concentration of
control serum was considered in the range defined
by the kit.
2.3.5. Determination antioxidant capacity of the
serum
Blood samples were collected from all animals
using cardiac puncture, and the serum was sepa-
rated by centrifugation. The Ferric Reducing Ability
of Plasma (FRAP) assay was applied for measuring
the total serum antioxidant capacity. This method is
based on the ability of the serum to reduce ferric-
tripiridyltriazine (Fe3þ-TPTZ) to a ferrous form
(Fe2þ), yielding a blue coloured complex (Fe2þ-
TPTZ) with maximum optical absorbance at 593 nm
[21].
2.3.6. Determination of serum MDA levels
For measuring serum MDA level, 0.5 g of thio-
barbituric acid was dissolved in 80 ml 20% acetic
acid and then the pH of the solution was set at 3.5 by
using NaOH. The final volume of the assay was then
adjusted to 100 ml by addition of 20% acetic acid.
Then, 100 ml of the serum sample was dissolved in
2.5 ml of the working solution and 100 ml of 8.1%
sodium dodecyl sulfate (SDS). The samples were left
in a water bath containing boiling water for 1 h and
then cooled and centrifuged at 4000 rpm. The su-
pernatant's optical absorbance was read at a wave-
length of 523 nm [22].
2.4. Statistical analysis
The data were presented as mean ± standard
error of measurement. Data analysis was performed
by one-way ANOVA and Tukey's test using version
7 of the GraphPad Prism software. Data were
considered statistically significant at the level of
P < 0.05.
3. Results
3.1. The effect of N. sativa seed oil on PI and PV
As Figs. 2 and 3illustrate, the highest PI and PV
are observed in the BPH model group and the
Fig. 1. Schematic of study design.
Fig. 2. Effect of Nigella sativa seed oil on prostate index; control:
Healthy rats, BPH model: Rats with BPH, BPHþ NS 400 (mg/kg): Rats
with BPH treated with 400 mg/kg N. sativa seed oil, BPHþ NS 800 (mg/
kg): Rats with BPH treated with 800 mg/kg N. sativa seed oil,
BPHþFinestride: Rats with BPH administered with 0.5 mg/kg finaste-
ride; *** significant difference with control group ( p < 0.001),
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lowest PI and PV levels in the control group
( p < 0.001). Oral treatment with 400 and 800 mg/kg
of the oil of N. sativa seed and finasteride signifi-
cantly decreased the PI and PV when compared to
the BPH model group ( p < 0.05).
3.2. The effect of N. sativa seed oil on DHT and
PSA concentrations
As shown in Figs. 4 and 5, the highest concen-
trations of DHT and PSA were observed in the BPH
model group while the lowest DHT and PSA con-
centrations were evident in the control group
( p < 0.001). Oral treatment with 400 and 800 mg/kg
of the oil of N. sativa seed and finasteride signifi-
cantly decreased the DHT and PSA concentrations
compared to the BPH model group ( p < 0.05). The
level of DHT also decreased significantly and more
markedly in both N. sativa seed oil-treated groups
when compared to the finasteride-treated group
(p < 0.05).
3.3. The effect of N. sativa seed oil on serum
antioxidant capacity and MDA levels
As Fig. 6 illustrates the lowest serum antioxidant
capacity level is observed in the BPH model group
and the highest serum antioxidant capacity level in
the control group ( p < 0.001). Treatment with 400
and 800 mg/kg N. sativa seed oil and finasteride
significantly increased the serum antioxidant ca-
pacity level concentration in comparison to the BPH
model group ( p < 0.05). The results showed that
treatment with 800 mg/kg of the oil of N. sativa seed
Fig. 3. Effect of Nigella sativa seed oil on prostate volume; control:
Healthy rats, BPH model: Rats with BPH, BPHþ NS 400 (mg/kg): Rats
with BPH treated with 400 mg/kg N. sativa seed oil, BPHþ NS 800 (mg/
kg): Rats with BPH treated with 800 mg/kg N. sativa seed oil,
BPHþFinestride: Rats with BPH administered with 0.5 mg/kg finaste-
ride; *** significant difference with control group ( p < 0.001), #, ###,
## significant difference with BPH model group ( p < 0.05, p < 0.001,
p < 001).
Fig. 4. Effect of Nigella sativa seed oil on dihydrotestosterone concen-
tration; control: Healthy rats, BPH model: Rats with BPH, BPHþ NS
400 (mg/kg): Rats with BPH treated with 400 mg/kg N. sativa seed oil,
BPHþ NS 800 (mg/kg): Rats with BPH treated with 800 mg/kg N. sativa
seed oil, BPHþFinestride: Rats with BPH administered with 0.5 mg/kg
finasteride; *** significant difference with control group ( p < 0.001),
### significant difference with BPH model group ( p < 0.001).
Fig. 5. Effect of Nigella sativa seed oil on prostate-specific antigen
concentration; control: Healthy rats, BPH model: Rats with BPH,
BPHþ NS 400 (mg/kg): Rats with BPH treated with 400 mg/kg N. sativa
seed oil, BPHþ NS 800 (mg/kg): Rats with BPH treated with 800 mg/kg
N. sativa seed oil, BPHþFinestride: Rats with BPH administered with
0.5 mg/kg finasteride; *** significant difference with control group
( p < 0.001), ###, ###, # significant difference with BPH model group
( p < 0.001, p < 0.001, p < 0.05).
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significantly increased the serum antioxidant ca-
pacity when compared to the finasteride receiving
group ( p < 0.001).
Figure 7 illustrates the effect of oral treatment with
N. sativa seed and finasteride oil on MDA concen-
tration. the highest MDA level is observed in the
BPH model group and the lowest MDA level in the
control group ( p < 0.001). Treatment with 400 and
800 mg/kg N. sativa seed oil significantly decreased
the MDA concentration in comparison to the BPH
model group ( p < 0.001). Besides, 800 mg/kg N.
sativa seed oil treatment led to a significant decrease
in MDA concentration when compared to the fi-
nasteride-treated group ( p < 0.05).
4. Discussion
The BPH is a non-malignant growth of the
epithelial and stromal cells of the prostate gland. 5a-
Reductase inhibitors and alpha-1-adrenergic an-
tagonists are two main agents commonly used to
treat BPH. 5a-Reductase is an essential enzyme that
converts testosterone to dihydrotestosterone
[23e25].
Finasteride is a classical 5a-reductase inhibitor
that decreases the DTH level, resulting in a decrease
in the PV and symptoms of patients with BPH
[26,27]. It has been well established that a1-adre-
noreceptor blockers relax prostatic smooth muscles
thereby increasing urine flow while decreasing the
prostate size and PSA [28]. The beneficial effects of
medicinal plants in treating BPH have already been
confirmed [8]. It has been well established that
medicinal plants used to treat BPH decrease the
plasma and prostate levels of the DHT and conse-
quently suppress prostate weight and size [29]. In
the current study and consistent with previous
studies [3,26,28,30], we observed that induction of
BPH led to increasing in PSA, DHT, PV, and PI in a
rat model. Besides that, our findings showed that N.
sativa seed oil treatment significantly mitigated
these pathological markers that both doses of the
400 and 800 mg/kg showed this effective effect.
In the current study, treatment with 400 and
800 mg/kg of the oil of N. sativa seed decreased the
DHT level. “Interestingly, we found that the N. sat-
iva oil partially at least decreased the DHT level in
the BPH model” more than that of finasteride. Hii-
pakka et al. reported that treatment with poly-
phenols isolated from green tea decreased the DHT
production, and inhibited prostate cells prolifera-
tion. Because N. sativa contains polyphenolic com-
pounds [31], it can be argued that, at least, inhibition
of 5a-reductase contributes to the beneficial effect of
this plant. The high amount of fatty acids of N. sativa
Fig. 6. Effect of Nigella sativa seed oil on serum antioxidant capacity;
control: Healthy rats, BPH model: Rats with BPH, BPHþ NS 400 (mg/
kg): Rats with BPH treated with 400 mg/kg N. sativa seed oil, BPHþ NS
800 (mg/kg): Rats with BPH treated with 800 mg/kg N. sativa seed oil,
BPHþFinestride: Rats with BPH administered with 0.5 mg/kg finaste-
ride; *** significant difference with control group ( p < 0.001), ###, ###,
## significant difference with BPH model group ( p < 0.001, p < 0.001,
p < 0.01).
Fig. 7. Effect of Nigella sativa seed oil on malondialdehyde concentra-
tion; control: Healthy rats, BPH model: Rats with BPH, BPHþ NS 400
(mg/kg): Rats with BPH treated with 400 mg/kg N. sativa seed oil,
BPHþ NS 800 (mg/kg): Rats with BPH treated with 800 mg/kg N. sativa
seed oil, BPHþFinestride: Rats with BPH administered with 0.5 mg/kg
finasteride; *** significant difference between control group and other
groups ( p < 0.001), ### significant difference with BPH model group
( p < 0.001).
BioMedicine
2021;11(1):19e25
A. SADEGHIMANESH ET AL














oil has essential unsaturated fatty acids (about 1%
omega-3, 25% omega-9 and 58% omega-6) in
abundance [10,12]. Abdel-Rahman et al. have
argued that compounds rich in fatty acids could
prevent prostate cells proliferation by lowering
testosterone and DHT concentrations [9]. Liang et al.
further demonstrated that fatty acids could inhibit
5a-reductase [10]. It has been shown that increased
prostate weight could be considered a marker to
diagnose BPH, while PI is often used to determine
the progression of BPH [20]. In the present study,
both 400 and 800 mg/kg doses of the oil of N. sativa
seed significantly decreased the PI and PV in BPH.
Recently, it has been demonstrated that PV and
PSA concentrations can be used to predict prostate
cells growth. In this regard, PSA can be considered
as an alternative index for PV and as a marker to
detect the risk of prostate carcinoma [20,32]. Hence,
an increased PSA level represents an increased
proliferation of prostate cells. In the current study,
treatment with 400 and 800 mg/kg N. sativa seed oil
significantly decreased the PSA concentration
compared to the BPH model group. Ren et al. re-
ported that polyphenols can suppress the level of
expression of PSA genes [33]. N. sativa's effect in
decreasing the PSA may thus be related to the
presence of polyphenols.
It has been determined that inflammation con-
tributes to the pathophysiology of BPH because in-
flammatory factors such as monocyte chemotactic
protein-1 are overexpressed. Hence the levels of
interleukin 10 receptor subunit alpha (IL-10RA) and
Interleukin 8 receptor, beta (IL-8RB) rise in the BPH
[34]. According to the study by Ragheb et al., thy-
moquinone isolated from N. sativa has an anti-in-
flammatory property and can decrease the
expression of the above-mentioned inflammatory
factors. It seems that N. sativa oil's effect can be to
some extent attributed to the presence of thymo-
quinone in N. sativa and the anti-inflammatory
property of this plant [35]. According to the study of
Jonas et al., the antioxidant activities of plants help
regulate cell proliferation and control in BPH [36]. It
has been demonstrated that an increase in the level
of MDA, which occurs in BPH, is a marker of lipid
peroxidation and/or tissues damage. Increased
MDA level in BPH has also been reported to be due
to OS [6]. Hence, treatment with antioxidants may
decrease the level of MDA and other pathological
markers of BPH. In our study, treatment with 400
and 800 mg/kg of the oil of N. sativa seed decreased
the serum MDA level, which is consistent with the
study by Hosseinzadeh et al. [37].
Also, in our study, treatment with 400 and 800 mg/
kg of the oil of N. sativa seed increased the serum
antioxidant capacity level. Houcher reported that
the oral treatment with N. sativa extract can cause an
increase in the FRAP capacity [38], which is consis-
tent with our results.
Therefore, it seems that N. sativa oil's effects to
inhibit lipid peroxidation and probably its anti-BPH
effects are due to the presence of antioxidant and
free radical-inhibiting compounds. The results on
the serum MDA levels in the current study further
demonstrated that these variables increased in the
BPH group in comparison to the control group. In
addition, the serum MDA levels decreased signifi-
cantly in N. sativa oil-treated groups in comparison
to the BPH group, which indicates the protective
effects of the compounds present in the N. sativa oil
could increase the antioxidant capacity of serum and
decrease the level of MDA. It seems that this
decrease in MDA levels is associated with the anti-
oxidant capacity of the plant.
5. Conclusion
According to the current study, N. sativa seed oil
in both doses of 400 and 800 mg/kg may have
application in treating BPH by decreasing the con-
centrations of DHT and PSA, and PI and PV and
exerting an antioxidant effect. Further studies are
required to isolate and identify the active compo-
nent(s) of the oil.
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